Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

NCT03317457 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

103

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Adult Soft Tissue Sarcoma
Recurrent Adult Soft Tissue Sarcoma

Interventions

BIOLOGICAL: Durvalumab and Tremelimumab
DRUG: Doxorubicin

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]